### Information about the product

| No | Information | | |
| --- | --- | --- | --- |
| 3 | Type of product  Chemical biocidal product  Biological biocidal product | | |
| 4 | Product name (Indicate complete name) | | |
| 5 | Product type  (According to Annex V to the Biocidal Products Directive, 98/8/EG) Mark the product type (PT) for the intended product. Note that the chosen PT must correspond with the working programme of 98/8/EG.  1  5  9  13  17 21  2  6  10  14  18 22  3  7  11  15  19 23  4  8  12  16  20 | | |
| 6 | Active substances/organisms | | |
| 6a | For **chemical** biocidal products:  List the CAS-numbers and full names for each of the active substances in the product | | |
| No | CAS no | Name of active substance |
| 1 |  |  |
| 2 |  |  |
| 3 |  |  |
| 4 |  |  |
| 5 |  |  |
| 6b | For **biological** biocidal products:  Type of organism  Micro-organism  Genetically modified organism  Nematodes, insects and/or arachnids | | |
| List the full names of the active organisms in the biocidal product | | |
| No | Name of organism | |
| 1 |  | |
| 2 |  | |
| 3 |  | |
| 4 |  | |
| 5 |  | |

### Information about the applicant

Current or future authorisation holder, i.e. the party **responsible** for initial placing of the biocidal product on the Swedish market.

| No | Information | | |
| --- | --- | --- | --- |
| 7 | Company name | Organisation number | |
| Street address | Telephone number | Fax number |
| Postal code and town | Contact person | |
| Country | E-mail address | |
| A registration certificate must be supplied by all companies that are not, or have not been, a registration holder/permanent representative or notifier of additional name, for an authorised product in Sweden over the past year. Registration certificates is also required if there have been changes since the last product authorisation.  Applicant´s registration certificate is attached, appendix no: | | |

### Information about **temporary** representative

**Representing** the future authorisation holder (i.e. the applicant in point 7) **only during the application procedure**

| No | Information | | |
| --- | --- | --- | --- |
| 8 | Company name | Organisation number | |
| Street address | Telephone number | Fax number |
| Postal code and town | Contact person | |
| Country | E-mail address | |
| A representative must prove the appointed level of representation by means of a **written letter of authorisation by the applicant in original**. It is always the applicant that is fully responsible for the placing of a biocidal product on the Swedish market. The representative is not the holder of the authorisation.  Letter of appointment as temporary representative is attached, appendix no: | | |

### Information about **permanent** representative

**Representing** the future authorisation holder (i.e. the applicant in point 7) also **during the approval period**

| No | Information | | |
| --- | --- | --- | --- |
| 9 | Company name | Organisation number | |
| Street address | Telephone number | Fax |
| Postal code and town | Contact person | |
| Country | E-mail address | |
| A representative must prove the appointed level of representation by means of a **written letter of authorisation by the applicant in original**. It is always the applicant that is fully responsible for the placing of a biocidal product on the Swedish market. The representative is not the holder of the authorisation.  Letter of appointment as permanent representative is attached, appendix no: | | |
| A registration certificate must be supplied by all companies that are not, or have not been, a registration holder/permanent representative or notifier of additional name, for an authorised product in Sweden over the past year. Registration certificates is also required if there have been changes since the last product authorisation.  Representative´s registration certificate is attached, appendix no: | | |

### Invoicing address for application fee

| No. | Information | |
| --- | --- | --- |
| 10 | Application fee will be paid by  Applicant  Temporary representative  Permanent representative | |
| Invoicing address | Contact person (name/e-mail/tel) |
| Postal code and town | Country |

### Other letters of authorisation

| No | Description | Appendix No |
| --- | --- | --- |
| 11 |  |  |
|  |  |
|  |  |

### Information about access to documentation

It must clearly be stated what studies this application (in the A- B- and C-forms) is based upon. Please notice that this is also obligatory in case of a re-authorisation application. For each data source used in this application (for each active substance or product) indicate whether this documentation is;

* owned by your company
* issued without valid data protection
* public material
* owned by another party from which a Letter of Access is enclosed

| No | Active substance or product study | Documen­tation owner \* | Documentation without valid data protection / public data | Letter of Access to other parties documentation obtained  (Enclose *Letter of Access* in original) |
| --- | --- | --- | --- | --- |
| 12 |  |  |  | Yes, appendix no: |
|  |  |  | Yes, appendix no: |
|  |  |  | Yes, appendix no: |
|  |  |  | Yes, appendix no: |

\* State preferred data protection alternatives in the attached reference list(s)

A reference list with all the studies that this application is based upon must be enclosed with each application. When access to the studies is given by a *Letter of Access* from another owner, that *Letter of Access* in original must accompany this application.

Please notice that all of the studies referred to in this application must be made available to the Swedish Chemicals Agency in full text, also those that a *Letter of Access* is provided for.

A *Letter of Access* attached to this application should be written according to the guidance provided for *Letter of Access* on the website of the Swedish Chemicals Agency (<https://www.kemi.se/download/18.164ad6b3172927a92896821c/1598103556697/guidance-document-loa_v4.pdf>).

In case reference is made to studies (if applicable accompanied by a *Letter of Access*) that are part of the evaluation process of active substances for uptake on Annex I of the Biocidal Products Directive (98/8/EG), these studies must also be made available to the Swedish Chemicals Agency in full text (document IV[[1]](#footnote-1)). Summaries of these studies (document III[[2]](#footnote-2)) may only be accepted if a draft report has been made available by the EU competent authority reporting member state (a Draft CAR[[3]](#footnote-3)).

### Signature

|  |  |
| --- | --- |
| Place and date | Signature ([[4]](#footnote-4)) |
|  | Name (please print) and company |

|  |  |
| --- | --- |
| **Send the application to:**  Kemikalieinspektionen  Box 2  SE-172 13 Sundbyberg, Sweden | **About payment of the application fee:**  The Swedish Chemicals Agency (KemI) makes a decision on the application fee and sends the decision together with an invoice. The invoice states the amount to be paid and how to pay it.  A list of application fees is available at KemI’s website. There is also a tool that helps you estimate the fee. |

1. Part of the competent authority report (CA-report) that contains reports/studies in full text. [↑](#footnote-ref-1)
2. Part of the competent authority report (CA-report) that contains reports/studies as summaries. [↑](#footnote-ref-2)
3. Competent Authority Report [↑](#footnote-ref-3)
4. Applicant or representative (with valid attached letter of authorisation) must sign this application form [↑](#footnote-ref-4)